Investors
Company Overview
AXIM Biotechnologies (OTC: AXIM) is an international healthcare solutions company targeting ocular biomarkers. AXIM Eye is working with two highly specialized Point-of-Care (POC) lab testing solutions designed specifically to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis.
Investor Presentation
Email Alerts
Stay informed and receive company updates straight to your inbox
Recent News
AXIM® Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing
Leading Diagnostic Healthcare Company Announces Provisional Patent Filing on Proprietary Use of Materials for Ophthalmological Test Strip Manufacturing SAN DIEGO, TBD DATE, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or...
AXIM® Biotechnologies Files Patent on Fentanyl Neutralizing Antibody Test, Applies for DEA License to Work With Controlled Substance
Diagnostic Healthcare Solutions Company Developing New Test Designed to Measure Neutralizing Antibodies of Deadly Opioid Fentanyl SAN DIEGO, TBD DATE, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...
AXIM Biotechnologies CEO Issues Letter to Shareholders
Summary: In 2022, AXIM® finalized optimization of its R&D and manufacturing infrastructure to be used in its diagnostic program AXIM will continue to generate revenue from its two FDA-cleared dry eye disease (DED) diagnostic tests through commercialization partner...
